Project Grant R00HL169940
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $685,212 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop policy-relevant evidence on the scope and effects of prior authorization (PA) for cardiovascular care. The project quantifies patient exposure to PA for cardiovascular services from 2016 through 2024, identifying which patient groups experience PA barriers and measuring how PA affects service use, care...
- The National Heart Lung and Blood Institute awarded the University of Pennsylvania $169,020 on April 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the genomic and clinical mechanisms of myocardial lipomatous metaplasia and its prognostic implications for cardiac dysfunction and arrhythmia. The recipient will apply a deep-learning segmentation model to cardiac CT images from the Penn Medicine Biobank (23,940 participants with genotypes and imaging as of...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $165,888 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the genetic architecture of heart failure with preserved ejection fraction (HFPEF) and identify novel therapeutic targets. The recipient will enhance a machine learning model trained to predict HFPEF by incorporating cardiac MRIs and electrocardiograms, improving model specificity for genomic...
- The National Heart, Lung, and Blood Institute awarded $1,476,944 to the University of Pennsylvania on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiovascular disease risk prediction models tailored to men with prostate cancer and determine their clinical impact. The award funds development of CVD absolute risk prediction models that incorporate cancer-specific variables, cardiotoxic cancer treatment effects including androgen deprivation...
- Federal Grant Award Summary The University of Pennsylvania received a $169,020 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 19, 2025, with completion targeted for August 31, 2027. This research project focuses on decoding nuclear mechanosignaling and epigenetic mediators of mechanical memory in cardiomyocytes—the process by which cardiac cells convert external mechanical signals into...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $632,081 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop conformation-sensitive platelet-hitchhiking lipid nanoparticles for targeted delivery of mRNA and small interfering RNA to infarcted heart tissue following myocardial infarction. The project addresses therapeutic limitations in post-infarction recovery by engineering lipid nanoparticles to...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $109,076 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop individualized prediction methods for heart failure progression using digital twins and explainable reinforcement learning. The project will characterize cardiac performance at the individual level using primary echocardiographic images, quantitative echocardiographic measures, and arterial pulse wave velocity...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded $1,137,435 to the University of Pennsylvania on March 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance therapeutic gene-editing approaches for cardiovascular and inherited disease. The recipient is developing and translating gene-editing therapies across three therapeutic domains. The first targets liver-centered, multiplex editing to prevent atherosclerotic cardiovascular disease through tunable...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $243,750 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing designation R03HL185220) to support research on occult hypoxemia prediction and long-term outcomes. Dr. Christopher Chesley will conduct a pilot study of prospectively enrolled critically ill adults receiving arterial lines during routine care in a high-volume medical intensive care unit. Through...
The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $237,153 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance predictive modeling of hospitalizations and emergency department visits for heart failure patients in managed long-term care settings through analysis of audio-recorded telephone communications between patients and care coordinators. The project, HEAR-HEARTFELT (Identifying the Risk of Hospitalizations or Emergency Department Visits for Patients with Heart Failure in Managed Long-Term Care Through Verbal Communication), builds on prior K99-phase work that identified clinically relevant risk factors embedded in patient-coordinator conversations using three complementary approaches: conversational characteristics analysis, linguistic indicators based on a curated lexicon of heart failure symptoms and psychosocial stressors, and acoustic feature extraction from voice signals. The R00 phase advances to predictive modeling incorporating these multimodal features and expands the data collection period. Heart failure remains a leading cause of unplanned hospitalizations and ED visits despite community-based care coordination programs designed to reduce such events; the project addresses an untapped source of temporally sensitive patient-status information in existing risk stratification models. Performance takes place in Philadelphia, Pennsylvania. The award period runs through June 30, 2029. This is a project grant, the standard NIH investigator-initiated research mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $237.2k | 8/21/26 |